Bionano Genomics, Inc. (NASDAQ: BNGO) shares were up 11.22% to 7.73 in the pre-market session after it announced that on that third day of its five-day Next-generation Cytogenomics Symposium, Bionano Genomics, Inc. (Nasdaq: BNGO) announced six Saphyr Users who shared their findings and interactions with the Saphyr optical genome mapping system (OGM) to analyze solid tumor genomes.
Get the hottest stocks to trade every day before the market opens 100% free. Click here now.
Sapphyr gives a description of the structural variation in the genome for the first time and offers the chance to identify new cancer generators, therapeutic priorities, and prognostic markers, as was not feasible with the subsequent generation sequencing (NGS) and array systems before now.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Read More
- Marathon Patent Group (MARA) to stay in action aligned with the Bitcoin Market
- Is Zomedica Corp. (ZOM) a Buy with the Recent Dip?
Company Profile
Bionano provides tools and services based on its Saphyr system to scientists and clinicians conducting genetic research and professional diagnostic testing for those with autism spectrum disorder (ASD) and other neurodevelopmental disabilities through its Lineagen business. Bionano’s Saphyr system enables researchers and clinicians to detect structural variations in cells or as part of a clinical trial that can be used for diagnostics and therapeutics.